Search results
Showing 166 to 180 of 887 results for score
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
Evidence-based recommendations on Prontosan for treating acute and chronic wounds.
Evidence-based recommendations on extracorporeal photopheresis for Crohn's disease. This involves collecting blood from the person, separating the white blood cells from the whole blood, treating with ultraviolet light and re-infusing into the person. The aim is to produce a generalised immune response against the cells that cause the inflammation.
View recommendations for HTG182Show all sections
Sections for HTG182
Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults.
Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults.
Show all sections
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.
Percutaneous transforaminal endoscopic lumbar discectomy for sciatica (HTG412)
Evidence-based recommendations on percutaneous transforaminal endoscopic lumbar discectomy for sciatica in adults. This involves removing part of the damaged spinal disc to relieve the symptoms of sciatica.
View recommendations for HTG412Show all sections
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Percutaneous closure of patent foramen ovale for recurrent migraine (HTG242)
Evidence-based recommendations on percutaneous closure of patent foramen ovale for recurrent migraine. This involves passing a device through a large vessel in the groin up into the heart and closing/blocking the hole in the wall of the heart.
View recommendations for HTG242Show all sections
Sections for HTG242